COGT
Cogent Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.50
−5.09%Sep 15, 2026, 12:00 UTC
The FDA accepted Cogent Biosciences' New Drug Application for bezuclastinib in patients with advanced systemic mastocytosis, supported by positive results from the APEX pivotal trial.
Sep 2, 2026, 20:25 UTC
Cogent Biosciences signed a five-year commercial supply agreement with Hovione FarmaCiencia S.A. for the purchase of bezuclastinib spray-dried dispersion and tablets, with automatic two-year renewals.
Aug 10, 2026, 00:00 UTC
Cogent Biosciences reported a net loss of $96.4 million for Q2 2026, with research and development expenses of $70.8 million and general and administrative expenses of $31.8 million.
Jun 30, 2026, 12:00 UTC
Cogent Biosciences submitted a New Drug Application (NDA) for bezuclastinib in advanced systemic mastocytosis (AdvSM) to the FDA.
Source: